• Je něco špatně v tomto záznamu ?

The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers

L. Schreiberhuber, C. Herzog, CD. Vavourakis, E. Redl, C. Kastner, A. Jones, I. Evans, M. Zikan, D. Cibula, P. Widschwendter, K. Pfau, B. Math, M. Seewald, S. Amory, P. Obrist, M. Widschwendter

. 2023 ; 152 (6) : 1269-1274. [pub] 20221001

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003818

The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of women suffering from vaginal bleeding actually have such a cancer. A simple, operator-independent and accurate test to correctly identify women presenting with abnormal bleeding as a consequence of endometrial or cervical cancer is urgently required. We have recently developed and validated the WID-qEC test, which assesses DNA methylation of ZSCAN12 and GYPC via real-time PCR, to triage women with symptoms suggestive of endometrial cancer using ThinPrep-based liquid cytology samples. Here, we investigated whether the WID-qEC test can additionally identify women with cervical cancer. Moreover, we evaluate the test's applicability in a SurePath-based hospital-cohort by comparing its ability to detect endometrial and cervical cancer to cytology. In a set of 23 cervical cancer cases and 28 matched controls the receiver operating characteristic (ROC) area under the curve (AUC) is 0.99 (95% confidence interval [CI]: 0.97-1.00) with a sensitivity and specificity of 100% and 92.9%, respectively. Amongst the hospital-cohort (n = 330), the ROC AUC is 0.99 (95% CI: 0.98-1) with a sensitivity and specificity of 100% and 82.5% for the WID-qEC test, respectively, and 33.3% and 96.9% for cytology (considering PAP IV/V as positive). Our data suggest that the WID-qEC test detects both endometrial and cervical cancer with high accuracy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003818
003      
CZ-PrNML
005      
20230425140912.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34275 $2 doi
035    __
$a (PubMed)36056582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Schreiberhuber, Lena $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000330659888
245    14
$a The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers / $c L. Schreiberhuber, C. Herzog, CD. Vavourakis, E. Redl, C. Kastner, A. Jones, I. Evans, M. Zikan, D. Cibula, P. Widschwendter, K. Pfau, B. Math, M. Seewald, S. Amory, P. Obrist, M. Widschwendter
520    9_
$a The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of women suffering from vaginal bleeding actually have such a cancer. A simple, operator-independent and accurate test to correctly identify women presenting with abnormal bleeding as a consequence of endometrial or cervical cancer is urgently required. We have recently developed and validated the WID-qEC test, which assesses DNA methylation of ZSCAN12 and GYPC via real-time PCR, to triage women with symptoms suggestive of endometrial cancer using ThinPrep-based liquid cytology samples. Here, we investigated whether the WID-qEC test can additionally identify women with cervical cancer. Moreover, we evaluate the test's applicability in a SurePath-based hospital-cohort by comparing its ability to detect endometrial and cervical cancer to cytology. In a set of 23 cervical cancer cases and 28 matched controls the receiver operating characteristic (ROC) area under the curve (AUC) is 0.99 (95% confidence interval [CI]: 0.97-1.00) with a sensitivity and specificity of 100% and 92.9%, respectively. Amongst the hospital-cohort (n = 330), the ROC AUC is 0.99 (95% CI: 0.98-1) with a sensitivity and specificity of 100% and 82.5% for the WID-qEC test, respectively, and 33.3% and 96.9% for cytology (considering PAP IV/V as positive). Our data suggest that the WID-qEC test detects both endometrial and cervical cancer with high accuracy.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory děložního čípku $x diagnóza $x genetika $x patologie $7 D002583
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a endometrium $x patologie $7 D004717
650    _2
$a cytodiagnostika $7 D003581
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a děložní krvácení $x diagnóza $x patologie $7 D014592
650    12
$a dysplazie děložního hrdla $x diagnóza $7 D002578
650    _2
$a vaginální stěr $7 D014626
650    12
$a infekce papilomavirem $x diagnóza $7 D030361
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Herzog, Chiara $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/000000021572498X
700    1_
$a Vavourakis, Charlotte D $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000250272309
700    1_
$a Redl, Elisa $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria
700    1_
$a Kastner, Christine $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria
700    1_
$a Jones, Allison $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Evans, Iona $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Zikan, Michal $u Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Bulovka University Hospital, Prague, Czech Republic
700    1_
$a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Widschwendter, Peter $u Department of Gynecology and Obstetrics, General Hospital Hall, Tirol Kliniken, Hall in Tirol, Austria $u Danube Private University (DPU), Krems an der Donau, Austria
700    1_
$a Pfau, Karin $u Department of Gynecology and Obstetrics, General Hospital Hall, Tirol Kliniken, Hall in Tirol, Austria
700    1_
$a Math, Barbara $u Tyrolpath Obrist Brunhuber GmbH, Zams, Austria
700    1_
$a Seewald, Martin $u Tyrolpath Obrist Brunhuber GmbH, Zams, Austria
700    1_
$a Amory, Sylvain $u Tyrolpath Obrist Brunhuber GmbH, Zams, Austria
700    1_
$a Obrist, Peter $u Tyrolpath Obrist Brunhuber GmbH, Zams, Austria
700    1_
$a Widschwendter, Martin $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK $u Department of Gynecology and Obstetrics, General Hospital Hall, Tirol Kliniken, Hall in Tirol, Austria $u Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000277788380
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 152, č. 6 (2023), s. 1269-1274
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36056582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140909 $b ABA008
999    __
$a ok $b bmc $g 1924471 $s 1190027
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 152 $c 6 $d 1269-1274 $e 20221001 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace